
TY  - JOUR
TI  - Abstracts of the 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders
JO  - Haemophilia
VL  - 16
IS  - 2
SN  - 1351-8216
UR  - https://doi.org/10.1111/j.1365-2516.2010.02182.x
DO  - doi:10.1111/j.1365-2516.2010.02182.x
SP  - 386
EP  - 412
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts cont.
JO  - Clinical Microbiology and Infection
VL  - 11
IS  - s2
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2005.clm_1134_02.x
DO  - doi:10.1111/j.1469-0691.2005.clm_1134_02.x
SP  - 238
EP  - 390
PY  - 2005
ER  - 

TY  - JOUR
AU  - MURAI-KUSHIYA, MAMI
AU  - OKADA, SATOSHI
AU  - KIMURA, TOSHIO
AU  - HASEGAWA, RYUICHI
TI  - Effects of turpentine oil pretreatment on β-blocker pharmacokinetic parameters in rats
JO  - Journal of Pharmacy and Pharmacology
VL  - 45
IS  - 9
SN  - 0022-3573
UR  - https://doi.org/10.1111/j.2042-7158.1993.tb05696.x
DO  - doi:10.1111/j.2042-7158.1993.tb05696.x
SP  - 836
EP  - 838
PY  - 1993
AB  - Abstract? Turpentine oil treatment (0·2 mL kg?1, s.c.) was used to increase the plasma concentration of α1-acid glycoprotein (0·13 mg mL?1 in control rats) to 1·72 mg mL?1 after 2 days, and allow assessment of its effects on the pharmacokinetics and stereoselective binding of three ?-blockers. Racemates (5 mg kg?1) were administered intravenously to control and turpentine oil-pretreated rats and the plasma concentrations were determined up to 90 min. Stereoselective analysis showed the apparent distribution volume and the area under plasma concentration-time curves (AUC) of R-(+)-propranolol to be, respectively, one-quarter and twice those of the S-(?)-enantiomer and differences in pharmacokinetic parameters between the two were magnified by turpentine oil pretreatment. Pharmacokinetic parameters of oxprenolol enantiomers were essentially similar for the controls but after turpentine oil pretreatment, a higher affinity of the R-(+)-enantiomer for plasma was observed. Acebutolol enantiomers behaved non-stereospecifically throughout. These results were consistent with predictions from the in-vitro stereospecific binding properties of these agents to purified rat α1-acid glycoprotein.
ER  - 

TY  - JOUR
AU  - Worthington, Patricia
AU  - Balint, Jane
AU  - Bechtold, Matthew
AU  - Bingham, Angela
AU  - Chan, Lingtak-Neander
AU  - Durfee, Sharon
AU  - Jevenn, Andrea K.
AU  - Malone, Ainsley
AU  - Mascarenhas, Maria
AU  - Robinson, Daniel T.
AU  - Holcombe, Beverly
TI  - When Is Parenteral Nutrition Appropriate?
JO  - Journal of Parenteral and Enteral Nutrition
JA  - Journal of Parenteral and Enteral Nutrition
VL  - 41
IS  - 3
SN  - 0148-6071
UR  - https://doi.org/10.1177/0148607117695251
DO  - doi:10.1177/0148607117695251
SP  - 324
EP  - 377
PY  - 2017
AB  - Parenteral nutrition (PN) represents one of the most notable achievements of modern medicine, serving as a therapeutic modality for all age groups across the healthcare continuum. PN offers a life-sustaining option when intestinal failure prevents adequate oral or enteral nutrition. However, providing nutrients by vein is an expensive form of nutrition support, and serious adverse events can occur. In an effort to provide clinical guidance regarding PN therapy, the Board of Directors of the American Society for Parenteral and Enteral Nutrition (ASPEN) convened a task force to develop consensus recommendations regarding appropriate PN use. The recommendations contained in this document aim to delineate appropriate PN use and promote clinical benefits while minimizing the risks associated with the therapy. These consensus recommendations build on previous ASPEN clinical guidelines and consensus recommendations for PN safety. They are intended to guide evidence-based decisions regarding appropriate PN use for organizations and individual professionals, including physicians, nurses, dietitians, pharmacists, and other clinicians involved in providing PN. They not only support decisions related to initiating and managing PN but also serve as a guide for developing quality monitoring tools for PN and for identifying areas for further research. Finally, the recommendations contained within the document are also designed to inform decisions made by additional stakeholders, such as policy makers and third-party payers, by providing current perspectives regarding the use of PN in a variety of healthcare settings.
ER  - 

TY  - JOUR
TI  - Poster Sessions: All Organs
JO  - American Journal of Transplantation
VL  - 14
IS  - S3
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.12887
DO  - doi:10.1111/ajt.12887
SP  - 233
EP  - 277
PY  - 2014
ER  - 

TY  - JOUR
TI  - Scientific Exhibits
JO  - Journal of Medical Radiation Sciences
JA  - J Med Radiat Sci
VL  - 61
IS  - S1
SN  - 2051-3895
UR  - https://doi.org/10.1002/jmrs.74
DO  - doi:10.1002/jmrs.74
SP  - 184
EP  - 343
PY  - 2014
ER  - 

TY  - JOUR
TI  - Scientific Exhibits
JO  - Journal of Medical Imaging and Radiation Oncology
JA  - Journal of Medical Imaging and Radiation Oncology
VL  - 58
IS  - S1
SN  - 1754-9477
UR  - https://doi.org/10.1111/1754-9485.12223
DO  - doi:10.1111/1754-9485.12223
SP  - 184
EP  - 343
PY  - 2014
ER  - 

TY  - JOUR
TI  - WORLD CONGRESS ON ABDOMINAL COMPARTMENT SYNDROME, QUEENSLAND, AUSTRALIA, DECEMBER 2004: SELECTED ABSTRACTS (www.wsacs.org)
JO  - ANZ Journal of Surgery
VL  - 75
IS  - 4
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2005.033657.x
DO  - doi:10.1111/j.1445-2197.2005.033657.x
SP  - A1
EP  - A23
PY  - 2005
ER  - 

TY  - JOUR
TI  - Paper Session Ethics & Quality of Life
JO  - Journal of the American Geriatrics Society
VL  - 56
IS  - s1
SN  - 0002-8614
UR  - https://doi.org/10.1111/j.1532-5415.2007.01743.x
DO  - doi:10.1111/j.1532-5415.2007.01743.x
SP  - 1
EP  - 211
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts-part X (Continue in Part XI)
JO  - Proceedings of the International Society for Magnetic Resonance in Medicine
JA  - Proc. Soc. Magn. Reson. Med.
VL  - 1992
IS  - S1
SN  - 1065-9889
UR  - https://doi.org/10.1002/mrmp.22419920112
DO  - doi:10.1002/mrmp.22419920112
SP  - 1407
EP  - 1609
PY  - 1992
ER  - 

TY  - JOUR
TI  - AASLD Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 56
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.26040
DO  - doi:10.1002/hep.26040
SP  - 191A
EP  - 1144A
PY  - 2012
ER  - 

TY  - JOUR
TI  - 44th Congress of the International Society of Paediatric Oncology (SIOP) 2012, London, United Kingdom, 5th–8th October, 2012 SIOP abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 59
IS  - 6
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.24295
DO  - doi:10.1002/pbc.24295
SP  - 965
EP  - 1152
PY  - 2012
ER  - 

TY  - JOUR
TI  - American Society for Laser Medicine and Surgery fifteenth annual meeting San Diego, California April 2-4, 1995 abstracts
JO  - Lasers in Surgery and Medicine
JA  - Lasers Surg. Med.
VL  - 17
IS  - S7
SN  - 0196-8092
UR  - https://doi.org/10.1002/lsm.1900170502
DO  - doi:10.1002/lsm.1900170502
SP  - 1
EP  - 82
PY  - 1995
ER  - 

TY  - JOUR
TI  - Poster Session: Haemostasis and Thrombosis
JO  - British Journal of Haematology
VL  - 149
IS  - s1
SN  - 0007-1048
UR  - https://doi.org/10.1111/j.1365-2141.2010.08116_1.x
DO  - doi:10.1111/j.1365-2141.2010.08116_1.x
SP  - 27
EP  - 96
PY  - 2010
ER  - 

TY  - JOUR
AU  - Ning, MingMing
AU  - Lopez, Mary
AU  - Cao, Jing
AU  - Buonanno, Ferdinando S.
AU  - Lo, Eng H.
TI  - Application of proteomics to cerebrovascular disease
JO  - ELECTROPHORESIS
JA  - ELECTROPHORESIS
VL  - 33
IS  - 24
SN  - 0173-0835
UR  - https://doi.org/10.1002/elps.201200481
DO  - doi:10.1002/elps.201200481
SP  - 3582
EP  - 3597
KW  - Biomarker
KW  - Cerebrovascular disease
KW  - Cerebrospinal fluid (CSF)
KW  - Mass spectrometry
KW  - Pharmaco-proteomics
KW  - Stroke
PY  - 2012
AB  - While neurovascular diseases such as ischemic and hemorrhagic stroke are the leading causes of disability in the world, the repertoire of therapeutic interventions has remained remarkably limited. There is a dire need to develop new diagnostic, prognostic, and therapeutic options. The study of proteomics is particularly enticing for cerebrovascular diseases such as stroke, which most likely involve multiple gene interactions resulting in a wide range of clinical phenotypes. Currently, rapidly progressing neuroproteomic techniques have been employed in clinical and translational research to help identify biologically relevant pathways, to understand cerebrovascular pathophysiology, and to develop novel therapeutics and diagnostics. Future integration of proteomic with genomic, transcriptomic, and metabolomic studies will add new perspectives to better understand the complexities of neurovascular injury. Here, we review cerebrovascular proteomics research in both preclinical (animal, cell culture) and clinical (blood, urine, cerebrospinal fluid, microdialyates, tissue) studies. We will also discuss the rewards, challenges, and future directions for the application of proteomics technology to the study of various disease phenotypes. To capture the dynamic range of cerebrovascular injury and repair with a translational targeted and discovery approach, we emphasize the importance of complementing innovative proteomic technology with existing molecular biology models in preclinical studies, and the need to advance pharmacoproteomics to directly probe clinical physiology and gauge therapeutic efficacy at the bedside.
ER  - 

TY  - JOUR
TI  - Podium Poster Presentations
JO  - BJU International
JA  - BJU Int
VL  - 119
IS  - S2
SN  - 1464-4096
UR  - https://doi.org/10.1111/bju.13750
DO  - doi:10.1111/bju.13750
SP  - 4
EP  - 42
PY  - 2017
ER  - 

TY  - JOUR
TI  - ABSTRACTS FROM CURRENT LITERATURE
JO  - British Journal of Urology
VL  - 30
IS  - 2
SN  - 0007-1331
UR  - https://doi.org/10.1111/j.1464-410X.1958.tb06240.x
DO  - doi:10.1111/j.1464-410X.1958.tb06240.x
SP  - 225
EP  - 231
PY  - 1958
ER  - 

TY  - JOUR
TI  - ABSTRACTS—POSTERS
JO  - Alcoholism: Clinical and Experimental Research
VL  - 32
IS  - s1
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2008.00685.x-i1
DO  - doi:10.1111/j.1530-0277.2008.00685.x-i1
SP  - 11A
EP  - 271A
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Artificial Organs
VL  - 31
IS  - 10
SN  - 0160-564X
UR  - https://doi.org/10.1111/j.1525-1594.2007.00491.x
DO  - doi:10.1111/j.1525-1594.2007.00491.x
SP  - A33
EP  - A100
PY  - 2007
ER  - 

TY  - JOUR
TI  - Keyword Index
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - s2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04382.x
DO  - doi:10.1111/j.1538-7836.2011.04382.x
SP  - 1028
EP  - 1055
PY  - 2011
ER  - 
